Moderna Q1 net loss $1.0B, revenue $108M; reiterates 2025 revenue guidance $1.5-2.5B

Moderna, Inc.

2025-Q1 EPS reported -$2.52 revenue$108,000,000

Q1 2025 revenue $108M (down 35% YoY); GAAP net loss $(1.0)B, EPS $(2.52).
Reiterates 2025 revenue guidance $1.5-2.5B; expects H1 revenue ~$0.2B due to seasonality.
Announces cost-cutting plan: reduce GAAP operating costs by $1.4-1.7B by 2027; new 2027 estimate $4.7-5.0B.
Pipeline milestones: next-gen COVID vaccine PDUFA May 31; RSV vaccine PDUFA June 12; flu/COVID combo approval targeted 2026.
Cash and investments $8.4B at March 31 (down from $9.5B at Dec 31); expects year-end ~$6B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.